Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All peginterferon lambda..
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchPeginterferon LambdaPeg.. Lambda (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ ICU admission -200% Improvement Relative Risk Hospitalization time -25% Viral clearance, day 14 12% Viral clearance, day 7 -67% Peg.. Lambda  Kim et al.  LATE TREATMENT  RCT Is late treatment with peginterferon lambda beneficial for COVID-19? RCT 14 patients in the USA (July 2020 - July 2021) Longer hospitalization with peginterferon lambda (not stat. sig., p=0.59) c19early.org Kim et al., Frontiers in Medicine, Feb 2023 Favors peg.. lambda Favors control

Peginterferon lambda for the treatment of hospitalized patients with mild COVID-19: A pilot phase 2 randomized placebo-controlled trial

Kim et al., Frontiers in Medicine, doi:10.3389/fmed.2023.1095828, NCT04343976
Feb 2023  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Very small RCT with 14 hospitalized patients in the USA showing no significant differences with peginterferon lambda. Viral load was improved, however 86% of treatment versus 14% of control patients received remdesivir, and the median baseline viral load for treatment patients was 3.6 log10 copies/ml versus 0 for control.
risk of ICU admission, 200.0% higher, RR 3.00, p = 1.00, treatment 1 of 7 (14.3%), control 0 of 7 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm).
hospitalization time, 25.0% higher, relative time 1.25, p = 0.59, treatment median 5.0 IQR 4.0 n=7, control median 4.0 IQR 5.0 n=7.
risk of no viral clearance, 12.5% lower, RR 0.88, p = 1.00, treatment 3 of 6 (50.0%), control 4 of 7 (57.1%), NNT 14, day 14.
risk of no viral clearance, 66.7% higher, RR 1.67, p = 0.59, treatment 5 of 7 (71.4%), control 3 of 7 (42.9%), day 7.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Kim et al., 24 Feb 2023, Single Blind Randomized Controlled Trial, placebo-controlled, USA, peer-reviewed, median age 54.0, 9 authors, study period 14 July, 2020 - 16 July, 2021, trial NCT04343976 (history). Contact: chung.raymond@mgh.harvard.edu.
This PaperPeg.. LambdaAll
Peginterferon lambda for the treatment of hospitalized patients with mild COVID-19: A pilot phase 2 randomized placebo-controlled trial
Myung-Ho Kim, Josh Elbaz, Nikolaus Jilg, Jenna L Gustafson, Min Xu, Dilara Hatipoglu, Eric Nohelty, Arthur Y Kim, Raymond T Chung
Frontiers in Medicine, doi:10.3389/fmed.2023.1095828
Background: This study aimed to investigate the efficacy and safety of subcutaneous injection of peginterferon lambda in patients hospitalized with COVID-19. Methods: In this study (NCT04343976), patients admitted to hospital with COVID-19 confirmed by RT-PCR from nasopharyngeal swab were randomly assigned within 48 h to receive peginterferon lambda or placebo in a 1:1 ratio. Participants were subcutaneously injected with a peginterferon lambda or saline placebo at baseline and day 7 and were followed up until day 14. Results: We enrolled 14 participants; 6 participants (85.7%) in the peginterferon lambda group and 1 participant (14.3%) in the placebo group were treated with remdesivir prior to enrollment. Fifty percent of participants were SARS-CoV-2 RNA negative at baseline although they tested SARS-CoV-2 RNA positive within 48 h of randomization. Among participants who were SARS-CoV-2 positive at baseline, 2 out of 5 participants (40%) in the peginterferon lambda group became negative at day 14, while 0 out of 2 participants (0%) in the placebo group achieved negativity for SARS-CoV-2 by day 14 (p > 0.05). The median change in viral load (log copies per ml) was +1.72 (IQR −2.78 to 3.19) in the placebo group and −2.22 (IQR −3.24 to 0.55) in the peginterferon lambda group at day 14 (p = 0.24). Symptomatic changes did not differ between the two groups. Peginterferon lambda was well tolerated with a few treatment-related adverse effects. Conclusion: Peginterferon lambda appears to accelerate SARS-CoV-2 viral load decline and improve plasma disease progression markers in hospitalized patients with COVID-19.
Results We enrolled 14 participants admitted to the Massachusetts General Hospital and with COVID-19 between July 14, 2020 and July 16, 2021. The median age was 54.0 (IQR 45.50 to 58.50), 11 participants (78.6%) were male, and 9 (64.3%) were Hispanic (Table 1 ; Supplementary Table 1 ). All 14 randomly assigned participants were initially injected with a placebo or peginterferon lambda within a median of 43.1 h (IQR 35.8 to 48.4) after testing SARS-CoV-2 positive. Thirteen participants (92.9%) completed 14 days of follow up with 1 participant in the placebo group lost to follow up after day 7 (Figure 1 ). The median baseline SARS-CoV-2 viral load was 1.38 log copies per ml (IQR 0.00 to 4.23), with 5 participants (71.4%) in the placebo group and 2 participants (28.6%) in the peginterferon lambda group having undetectable viral load on the day of randomization although they were tested SARS-CoV-2 RNA positive within 48 h of randomization. The median sum of symptom scores was 2.00 (IQR 0.00 to 4.00) in the placebo group and 5.50 (IQR 2.75 to 7.50) in the peginterferon lambda group. Six participants (85.7%) in the peginterferon lambda group and Ethics statement The studies involving human participants were reviewed and approved by Massachusetts General Hospital. The patients/participants provided their written informed consent to participate in this study. Author contributions MHK, NJ, AK, and RC contributed to study conception and design. MHK, JE, JG, and EN contributed to..
References
Akinbolade, Coughlan, Fairbairn, Mcconkey, Powell et al., Combination therapies for COVID-19: an overview of the clinical trials landscape, Br J Clin Pharmacol, doi:10.1111/bcp.15089
Barratt-Due, Olsen, Ic, Nezvalova-Henriksen, Kåsine et al., Evaluation of the effects of remdesivir and hydroxychloroquine on viral clearance in COVID-19: a randomized trial, Ann Intern Med, doi:10.7326/M21-0653
Beigel, Tomashek, Dodd, Mehta, Zingman et al., Remdesivir for the treatment of Covid-19-final report, N Engl J Med, doi:10.1056/NEJMoa2007764
Chan, Ahn, Sh, Chang, Peng et al., Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: a randomized phase 2b study (LIRA-B), J Hepatol, doi:10.1016/j.jhep.2015.12.018
Cochrane Haematology Groupansems, Grundeis, Dahms, Mikolajewska, Thieme, Remdesivir for the treatment of COVID-19, Cochrane Database Syst Rev, doi:10.1002/14651858.CD014962
Feld, Kandel, Biondi, Mj, Kozak et al., Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial, Lancet Respir Med, doi:10.1016/S2213-2600(20)30566-X
Forero, Ozarkar, Li, Lee, Ch et al., Differential activation of the transcription factor IRF1 underlies the distinct immune responses elicited by type I and type III Interferons, Immunity, doi:10.1016/j.immuni.2019.07.007
Hruska, Adamczyk, Colston, Hesney, Stonier et al., The pharmacokinetics of peginterferon lambda-1a following single dose administration to subjects with impaired renal function, Br J Clin Pharmacol, doi:10.1038/s41586-020-2708-8
Jagannathan, Andrews, Bonilla, Hedlin, Jacobson et al., Peginterferon lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial, Nat Commun, doi:10.1038/s41467-021-22177-1
Lingas, Néant, Gaymard, Belhadi, Peytavin et al., Effect of remdesivir on viral dynamics in COVID-19 hospitalized patients: a modelling analysis the randomized, controlled, open-label DisCoVeRy trial, J Antimicrob Chemother, doi:10.1093/jac/dkac048
Muir, Arora, Everson, Flisiak, George et al., A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection, J Hepatol, doi:10.1016/j.jhep.2014.07.022
Nair, Jacob, Hung, If, Lung et al., Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial, J Basic Clin Pharm, doi:10.1016/S0140-6736(20)31042-4
Park, Iwasaki, Type I and type III Interferons -induction, signaling, evasion, and application to combat COVID-19, Cell Host Microbe, doi:10.1016/j.chom.2020.05.008
Sims, Krishnan, Chang, Engle, Casalini et al., Characterization of the cytokine storm reflects hyperinflammatory endothelial dysfunction in COVID-19, J Allergy Clin Immunol, doi:10.1016/j.jaci.2020.08.031
Yang, Shen, Li, Yuan, Wei et al., Observational cohort study of IP-10's potential as a biomarker to aid in inflammation regulation within a clinical decision support protocol for patients with severe COVID-19, J Allergy Clin Immunol, doi:10.1371/journal.pone.0245296
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit